Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1987 Jun 13;294(6586):1504–1505. doi: 10.1136/bmj.294.6586.1504

Use and abuse of allopurinol.

J S Cameron, H A Simmonds
PMCID: PMC1246665  PMID: 3607420

Full text

PDF
1504

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablin A., Stephens B. G., Hirata T., Wilson K., Williams H. E. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism. 1972 Aug;21(8):771–778. doi: 10.1016/0026-0495(72)90124-2. [DOI] [PubMed] [Google Scholar]
  2. Band P. R., Silverberg D. S., Henderson J. F., Ulan R. A., Wensel R. H., Banerjee T. K., Little A. S. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970 Aug 13;283(7):354–357. doi: 10.1056/NEJM197008132830708. [DOI] [PubMed] [Google Scholar]
  3. Beck L. H. Requiem for gouty nephropathy. Kidney Int. 1986 Aug;30(2):280–287. doi: 10.1038/ki.1986.179. [DOI] [PubMed] [Google Scholar]
  4. Berlinger W. G., Park G. D., Spector R. The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med. 1985 Sep 26;313(13):771–776. doi: 10.1056/NEJM198509263131302. [DOI] [PubMed] [Google Scholar]
  5. Brock W. A., Golden J., Kaplan G. W. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol. 1983 Jul;130(1):157–159. doi: 10.1016/s0022-5347(17)51011-3. [DOI] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Dan M., Jedwab M., Peled M., Shibolet S. Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol. 1984 Mar;23(2):142–144. doi: 10.1111/j.1365-4362.1984.tb05689.x. [DOI] [PubMed] [Google Scholar]
  8. Elion G. B., Benezra F. M., Beardmore T. D., Kelley W. N. Studies with allopurinol in patients with impaired renal function. Adv Exp Med Biol. 1980;122A:263–267. doi: 10.1007/978-1-4615-9140-5_43. [DOI] [PubMed] [Google Scholar]
  9. Elion G. B., Yü T. F., Gutman A. B., Hitchings G. H. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968 Jul;45(1):69–77. doi: 10.1016/0002-9343(68)90008-9. [DOI] [PubMed] [Google Scholar]
  10. Ettinger B., Tang A., Citron J. T., Livermore B., Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986 Nov 27;315(22):1386–1389. doi: 10.1056/NEJM198611273152204. [DOI] [PubMed] [Google Scholar]
  11. Fong P. H., Ratnagopal P., Wong K. L. Drug induced toxic epidermal necrolysis. Singapore Med J. 1984 Jun;25(3):184–186. [PubMed] [Google Scholar]
  12. Gibson T., Highton J., Potter C., Simmonds H. A. Renal impairment and gout. Ann Rheum Dis. 1980 Oct;39(5):417–423. doi: 10.1136/ard.39.5.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gomez G. A., Stutzman L., Chu T. M. Xanthine nephropathy during chemotherapy in deficiency of hypoxanthine-guanine phosphoribosyltransferase. Arch Intern Med. 1978 Jun;138(6):1017–1019. doi: 10.1001/archinte.138.6.1017. [DOI] [PubMed] [Google Scholar]
  14. Greene M. L., Fujimoto W. Y., Seegmiller J. E. Urinary xanthine stones--a rare complications of allopurinol therapy. N Engl J Med. 1969 Feb 20;280(8):426–427. doi: 10.1056/NEJM196902202800806. [DOI] [PubMed] [Google Scholar]
  15. Guérin C., Genin C., Toulon J., Sabatier J. C., Leroy G., Berthoux F. Toxicité sévère de l'allopurinol. A propos d'un cas. Nephrologie. 1986;7(2):47–49. [PubMed] [Google Scholar]
  16. HAYES C. P., Jr, METZ E. N., ROBINSON R. R., RUNDLES R. W. THE USE OF ALLOPURINOL (HPP) TO CONTROL HYPERURICEMIA IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS. Trans Am Soc Artif Intern Organs. 1965;11:247–254. doi: 10.1097/00002480-196504000-00047. [DOI] [PubMed] [Google Scholar]
  17. Hande K. R., Hixson C. V., Chabner B. A. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res. 1981 Jun;41(6):2273–2279. [PubMed] [Google Scholar]
  18. Hande K. R., Noone R. M., Stone W. J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984 Jan;76(1):47–56. doi: 10.1016/0002-9343(84)90743-5. [DOI] [PubMed] [Google Scholar]
  19. Hande K., Reed E., Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978 May;23(5):598–605. doi: 10.1002/cpt1978235598. [DOI] [PubMed] [Google Scholar]
  20. Magner P., Sweet J., Bear R. A. Granulomatous interstitial nephritis associated with allopurinol therapy. CMAJ. 1986 Sep 1;135(5):496–497. [PMC free article] [PubMed] [Google Scholar]
  21. Manzke H., Harms D., Dörner K. Zur Problematik der Behandlung der kongenitalen Hyperurikämie. Monatsschr Kinderheilkd. 1971 Jul;119(7):424–428. [PubMed] [Google Scholar]
  22. McInnes G. T., Lawson D. H., Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981 Jun;40(3):245–249. doi: 10.1136/ard.40.3.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mizuno T., Segawa M., Kurumada T., Maruyama H., Onisawa J. Clinical and therapeutic aspects of the Lesch-Nyhan syndrome in Japanese children. Neuropadiatrie. 1970 Aug;2(1):38–52. doi: 10.1055/s-0028-1091839. [DOI] [PubMed] [Google Scholar]
  24. Ogawa A., Watanabe K., Minejima N. Renal xanthine stone in Lesch-Nyhan syndrome treated with allopurinol. Urology. 1985 Jul;26(1):56–58. doi: 10.1016/0090-4295(85)90256-0. [DOI] [PubMed] [Google Scholar]
  25. Ohsawa T., Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell Clin Pharm. 1985 Jun;19(6):431–433. doi: 10.1177/106002808501900606. [DOI] [PubMed] [Google Scholar]
  26. Oka T., Utsunomiya M., Ichikawa Y., Koide T., Takaha M., Mimaki T., Sonoda T. Xanthine calculi in the patient with the Lesch-Nyhan syndrome associated with urinary tract infection. Urol Int. 1985;40(3):138–140. doi: 10.1159/000281067. [DOI] [PubMed] [Google Scholar]
  28. Paton A. The politics of alcohol. Br Med J (Clin Res Ed) 1985 Jan 5;290(6461):1–2. doi: 10.1136/bmj.290.6461.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Reiter S., Simmonds H. A., Webster D. R., Watson A. R. On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency. Biochem Pharmacol. 1983 Jul 15;32(14):2167–2174. doi: 10.1016/0006-2952(83)90222-8. [DOI] [PubMed] [Google Scholar]
  30. Rosenfeld J. B. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Adv Exp Med Biol. 1974;41:581–596. doi: 10.1007/978-1-4757-1433-3_28. [DOI] [PubMed] [Google Scholar]
  31. Rundles R. W. The development of allopurinol. Arch Intern Med. 1985 Aug;145(8):1492–1503. [PubMed] [Google Scholar]
  32. Simmonds H. A., Cameron J. S., Morris G. S., Davies P. M. Allopurinol in renal failure and the tumour lysis syndrome. Clin Chim Acta. 1986 Oct 31;160(2):189–195. doi: 10.1016/0009-8981(86)90141-5. [DOI] [PubMed] [Google Scholar]
  33. Simmonds H. A., Warren D. J., Cameron J. S., Potter C. F., Farebrother D. A. Familial gout and renal failure in young women. Clin Nephrol. 1980 Oct;14(4):176–182. [PubMed] [Google Scholar]
  34. Singer J. Z., Wallace S. L. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986 Jan;29(1):82–87. doi: 10.1002/art.1780290111. [DOI] [PubMed] [Google Scholar]
  35. Sperling O., Brosh S., Boer P., Liberman U. A., De Vries A. Urinary xanthine stones in an allopurinol-treated gouty patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase. Isr J Med Sci. 1978 Feb;14(2):288–292. [PubMed] [Google Scholar]
  36. Stein C. M. Allopurinol hypersensitivity. A case report. S Afr Med J. 1985 Jun 8;67(23):935–936. [PubMed] [Google Scholar]
  37. Unreviewed reports. Br Med J (Clin Res Ed) 1985 Dec 14;291(6510):1688–1688. [PMC free article] [PubMed] [Google Scholar]
  38. Vanderstigel M., Zafrani E. S., Lejonc J. L., Schaeffer A., Portos J. L. Allopurinol hypersensitivity syndrome as a cause of hepatic fibrin-ring granulomas. Gastroenterology. 1986 Jan;90(1):188–190. doi: 10.1016/0016-5085(86)90092-2. [DOI] [PubMed] [Google Scholar]
  39. Webster E., Panush R. S. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum. 1985 Jun;28(6):707–709. doi: 10.1002/art.1780280617. [DOI] [PubMed] [Google Scholar]
  40. Wood M. H., Sebel E., O'Sullivan W. J. Allopurinol and thiazides. Lancet. 1972 Apr 1;1(7753):751–751. doi: 10.1016/s0140-6736(72)90271-1. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES